Danny Williams
Channel Management and Compliance
Expertise:
With more than two decades of account management, business development, and sales experience, Danny is well suited to lead the channel services team at EVERSANA.
He has partnered with clients to develop solutions to increase market share, cut costs, and increase revenue in today’s complex and ever-changing marketplace.
Danny’s prior experience includes pharmaceutical account management on both the pharma and agency sides of the industry, as well as sales analytics and project management roles in global consumer businesses.
He holds an MBA from Mississippi College and a BBA from the University of Mississippi.
Articles by Danny Williams
From Limitations to Expansions: How Prioritizing Patients’ Speed to Therapy Drives Therapy Adoption
Navigating the launch of a new product is a complex and ever-evolving journey for manufacturers. With hundreds of millions of dollars and an abundance of other significant resources invested in a product’s pre-launch commercialization efforts, meeting launch expectations is vital to ensure success and viability, and, most importantly, effectively provide treatment to patients in need. The majority of new products fail to meet launch expectations, but the EVERSANA COMPLETE Commercialization® model provides manufacturers with invaluable expertise to identify problem areas, develop innovative strategies to reverse a downward trajectory, expand patient access and much more. In this case study, learn how EVERSANA helped Evoke Pharma, a small biotech pharmaceutical company, revive a […]
Trade & Channel Strategies: Partnership Pavilion Panel
Panel Summary: The challenges of commercialization are abundant. Now more than ever, the right partner and understanding the patient journey are pivotal to commercialization success and ensuring patient access to therapy. During this panel, EVERSANA, EVOKE and UpScriptHealth experts discuss the launch and later pivot in strategy of a novel therapy. Speed to therapy initiation is crucial for patients of this indication to avoid isolation due to symptoms; however, diagnosis takes an average of 5 years and 5+ providers. There is also difficulty often associated with Rx approval. EVOKE had four full-time employees that spent 15 years working towards obtaining therapy approval but did not participate in pre-commercialization activities due […]
Pharmaceutical Distribution – Right-Sizing the Channel Strategy for Maximum Impact
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is too cumbersome, they forfeit the flexibility needed to increase efficiency, maximize return on investment and minimize risk on a product-by-product basis. Alternatively, implementing a lean, customized distribution channel developed in close partnership with an experienced, end-to-end service provider enables improved visibility into all stages of product movement while helping to deliver therapies wherever the patient needs them — to pharmacies, hospitals, clinics and residences — with accurate, on-time delivery. The goal is to create […]
Ask the Expert: e-Commerce Solutions for Channel Management
Many manufacturers involuntarily commit to convoluted, costly distribution models that often lack the flexibility needed to increase efficiency, maximize investments and minimize risk on a product-by-product basis. In this traditional model of working exclusively with large wholesalers and specialty distributors, they are incurring high fees to ensure channel access to pharmacies, hospitals and providers. Throughout this Q&A, Danny Williams, EVERSANA’s President of Channel Management, and Pat McGinn, Senior Vice President of Supply Chain Integration, share how EVERSANA’s e-Commerce platform is disrupting the industry to provide manufacturers a better option to reach downstream customers: a direct-to-provider selling model. Download this comprehensive Q&A to learn the answers to these questions: What is […]
Ensuring Speed, Scale and Certainty in Supply Chain
Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or pitfalls) that manufacturers must address in their channel distribution strategy: How quickly can you get your product into your patients’ hands? What will happen tomorrow if demand doubles tomorrow? Are you prepared for regulatory scrutiny? Download “Navigating Channel Distribution in a New (and more complex) Biopharma World” to learn how to ensure economic success and operational efficiency.
Breaking the Cycle of Supply Chain Complexity
As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can break the cycle of complexity within the supply chain to better connect patients to therapy, leverage distribution operations to their advantage, and create value across the entire product life cycle. Download the full article to learn how an agile business model can ensure your products are stored and distributed to the highest level of industry standards.
Navigating the Cycle of Supply Chain Complexity
As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can break the cycle of complexity within the supply chain to better connect patients to therapy, leverage distribution operations to their advantage, and create value across the entire product life cycle. Download the full article to learn how an agile business model can ensure your products are stored and distributed to the highest level of industry standards.
Navigating Channel Distribution in a New (and more complex) Biopharma World
Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or pitfalls) that manufacturers must address in their channel distribution strategy: How quickly can you get your product into your patients’ hands? What will happen tomorrow if demand doubles tomorrow? Are you prepared for regulatory scrutiny? Download “Navigating Channel Distribution in a New (and more complex) Biopharma World” to learn how to ensure economic success and operational efficiency.